KITLG and neoplasm: Ubiquitination (via RNF145, SCF-FBXW7, TRC8) inhibits SREBP2 activation, reducing cholesterol synthesis and tumor growth. Deubiquitination by USP28 stabilizes SREBP2, enhancing cholesterol synthesis and lipid metabolism.